@article{84f32cdfc61e4e189c35c43cbb779903,
title = "Commentary: Neoadjuvant checkpoint inhibitors in resectable non–small cell lung cancer—Ready for prime time?",
author = "Boris Sepesi and Tina Cascone",
note = "Funding Information: Disclosures: Dr Cascone has received speaker's fees from the Society for Immunotherapy of Cancer and Bristol-Myers Squibb, receives consultant fees from MedImmune and Bristol-Myers Squibb, and receives research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune, and Bristol-Myers Squibb. Dr Sepesi has nothing to disclose with regard to commercial support.",
year = "2020",
month = apr,
doi = "10.1016/j.jtcvs.2019.09.042",
language = "English (US)",
volume = "159",
pages = "1624--1625",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "4",
}